The difference here is that this randomized data has mirrored all the previous non-randomized data which did show improvement to survival numbers which IMO puts it in a category of just a little bit better than the normal phase II randomized trial. It should stand to reason that the add'l endpoints will follow the previous non randomized results.
News 
Market Data 
Discover 
AI
